Nature Communications (Oct 2022)
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
- Sophie A. Herbst,
- Mattias Vesterlund,
- Alexander J. Helmboldt,
- Rozbeh Jafari,
- Ioannis Siavelis,
- Matthias Stahl,
- Eva C. Schitter,
- Nora Liebers,
- Berit J. Brinkmann,
- Felix Czernilofsky,
- Tobias Roider,
- Peter-Martin Bruch,
- Murat Iskar,
- Adam Kittai,
- Ying Huang,
- Junyan Lu,
- Sarah Richter,
- Georgios Mermelekas,
- Husen Muhammad Umer,
- Mareike Knoll,
- Carolin Kolb,
- Angela Lenze,
- Xiaofang Cao,
- Cecilia Österholm,
- Linus Wahnschaffe,
- Carmen Herling,
- Sebastian Scheinost,
- Matthias Ganzinger,
- Larry Mansouri,
- Katharina Kriegsmann,
- Mark Kriegsmann,
- Simon Anders,
- Marc Zapatka,
- Giovanni Del Poeta,
- Antonella Zucchetto,
- Riccardo Bomben,
- Valter Gattei,
- Peter Dreger,
- Jennifer Woyach,
- Marco Herling,
- Carsten Müller-Tidow,
- Richard Rosenquist,
- Stephan Stilgenbauer,
- Thorsten Zenz,
- Wolfgang Huber,
- Eugen Tausch,
- Janne Lehtiö,
- Sascha Dietrich
Affiliations
- Sophie A. Herbst
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Mattias Vesterlund
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Alexander J. Helmboldt
- European Molecular Biology Laboratory (EMBL)
- Rozbeh Jafari
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Ioannis Siavelis
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Matthias Stahl
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Eva C. Schitter
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Nora Liebers
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Berit J. Brinkmann
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Felix Czernilofsky
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Tobias Roider
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Peter-Martin Bruch
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Murat Iskar
- Division of Molecular Genetics, German Cancer Research Center (DKFZ)
- Adam Kittai
- Department of Internal Medicine, Division of Hematology, The Ohio State University
- Ying Huang
- Department of Internal Medicine, Division of Hematology, The Ohio State University
- Junyan Lu
- European Molecular Biology Laboratory (EMBL)
- Sarah Richter
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Georgios Mermelekas
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Husen Muhammad Umer
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Mareike Knoll
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Carolin Kolb
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Angela Lenze
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Xiaofang Cao
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Cecilia Österholm
- Department of Molecular Medicine and Surgery, Karolinska Institutet
- Linus Wahnschaffe
- Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf (CIO ABCD), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne
- Carmen Herling
- Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf (CIO ABCD), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne
- Sebastian Scheinost
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
- Matthias Ganzinger
- Institute of Medical Biometry and Informatics, Heidelberg University
- Larry Mansouri
- Department of Molecular Medicine and Surgery, Karolinska Institutet
- Katharina Kriegsmann
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Mark Kriegsmann
- Institute of Pathology, University of Heidelberg
- Simon Anders
- Center for Molecular Biology of the University of Heidelberg (ZMBH)
- Marc Zapatka
- Division of Molecular Genetics, German Cancer Research Center (DKFZ)
- Giovanni Del Poeta
- Division of Hematology, University of Tor Vergata
- Antonella Zucchetto
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
- Riccardo Bomben
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
- Valter Gattei
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS
- Peter Dreger
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Jennifer Woyach
- Department of Internal Medicine, Division of Hematology, The Ohio State University
- Marco Herling
- Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf (CIO ABCD), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne
- Carsten Müller-Tidow
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- Richard Rosenquist
- Department of Molecular Medicine and Surgery, Karolinska Institutet
- Stephan Stilgenbauer
- Department of Internal Medicine III, University of Ulm
- Thorsten Zenz
- Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
- Wolfgang Huber
- European Molecular Biology Laboratory (EMBL)
- Eugen Tausch
- Department of Internal Medicine III, University of Ulm
- Janne Lehtiö
- Department of Oncology-Pathology, Karolinska Institute and Science for Life Laboratory
- Sascha Dietrich
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg
- DOI
- https://doi.org/10.1038/s41467-022-33385-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Proteomics can be used to refine cancer classification. Here, the authors characterise chronic lymphocytic leukaemia patients by proteogenomics, and identified a subtype of patients with poor prognosis associated with aberrant B cell receptor signalling.
